Literature DB >> 22854237

Bortezomib-induced thrombotic thrombocytopaenic purpura.

Neha Mehta1, Ashish Saxena, Ruben Niesvizky.   

Abstract

Thrombotic thrombocytopaenic purpura (TTP) is a thrombotic microangiopathy characterised by haemolytic anaemia, schistocytes on peripheral blood smear and thrombocytopaenia that can additionally present with fever, renal insufficiency and/or neurological abnormalities. While our understanding of idiopathic TTP has significantly advanced, there are still many unanswered questions regarding the pathophysiology of secondary TTP, which can be associated with malignancy, pregnancy, HIV infection, bone marrow transplantation and exposure to certain drugs including several chemotherapeutic agents. Here we present a case of bortezomib-associated TTP. Our patient developed microangiopathic haemolytic anaemia, thrombocytopaenia and altered mental status after her ninth dose of bortezomib. The drug was subsequently discontinued and the patient underwent one session of plasma exchange with clinical improvement and recovery of her platelet counts, disappearance of schistocytes and resolution of both neurological symptoms and haemolysis in 2 days.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22854237      PMCID: PMC4544112          DOI: 10.1136/bcr-2012-006461

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma.

Authors:  Rena Morita; Satoshi Hashino; Shinichi Shirai; Noriaki Fujita; Masahiro Onozawa; Kaoru Kahata; Takeshi Kondo; Masahiro Imamura; Masahiro Asaka
Journal:  Int J Hematol       Date:  2008-07-19       Impact factor: 2.490

2.  Cyclosporine and tacrolimus-associated thrombotic microangiopathy.

Authors:  P T Pham; A Peng; A H Wilkinson; H A Gritsch; C Lassman; P C Pham; G M Danovitch
Journal:  Am J Kidney Dis       Date:  2000-10       Impact factor: 8.860

Review 3.  Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib.

Authors:  H Moore; K Romeril
Journal:  Intern Med J       Date:  2011-04       Impact factor: 2.048

Review 4.  Drug-induced thrombotic microangiopathy.

Authors:  Anaadriana Zakarija; Charles Bennett
Journal:  Semin Thromb Hemost       Date:  2005-12       Impact factor: 4.180

Review 5.  How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

Authors:  J N George
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

Review 6.  Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature.

Authors:  J L Gottschall; B Neahring; J G McFarland; G G Wu; L A Weitekamp; R H Aster
Journal:  Am J Hematol       Date:  1994-12       Impact factor: 10.047

Review 7.  Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry.

Authors:  J B Lesesne; N Rothschild; B Erickson; S Korec; R Sisk; J Keller; M Arbus; P V Woolley; L Chiazze; P S Schein
Journal:  J Clin Oncol       Date:  1989-06       Impact factor: 44.544

8.  Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration.

Authors:  Anaadriana Zakarija; Nicholas Bandarenko; Dilip K Pandey; Amy Auerbach; Dennis W Raisch; Benjamin Kim; Hau C Kwaan; June M McKoy; Brian P Schmitt; Charles J Davidson; Paul R Yarnold; Philip B Gorelick; Charles L Bennett
Journal:  Stroke       Date:  2004-01-05       Impact factor: 7.914

9.  Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Richard M Kaufman; Lawrence T Goodnough; J Evan Sadler
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

10.  Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

Authors:  C B Reeder; D E Reece; V Kukreti; C Chen; S Trudel; J Hentz; B Noble; N A Pirooz; J E Spong; J G Piza; V H J Zepeda; J R Mikhael; J F Leis; P L Bergsagel; R Fonseca; A K Stewart
Journal:  Leukemia       Date:  2009-02-19       Impact factor: 11.528

  10 in total
  8 in total

Review 1.  Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.

Authors:  Rimda Wanchoo; Ala Abudayyeh; Mona Doshi; Amaka Edeani; Ilya G Glezerman; Divya Monga; Mitchell Rosner; Kenar D Jhaveri
Journal:  Clin J Am Soc Nephrol       Date:  2016-09-21       Impact factor: 8.237

2.  Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.

Authors:  Liliane Hobeika; Sally E Self; Juan Carlos Q Velez
Journal:  BMC Nephrol       Date:  2014-09-30       Impact factor: 2.388

3.  Renal and pulmonary thrombotic microangiopathy triggered by proteasome-inhibitor therapy in patient with smoldering myeloma: A renal biopsy and autopsy case report.

Authors:  Clarissa A Cassol; Michael P A Williams; Tiffany N Caza; Sophia Rodriguez
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

4.  Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma.

Authors:  Michael Rassner; Rebecca Baur; Andreas Mackensen; Monika Engelhardt; Ralph Wäsch; Mario Schiffer; Johanna Schneider
Journal:  BMC Nephrol       Date:  2021-01-18       Impact factor: 2.388

5.  Unique Presentation of Bortezomib-Associated Thrombotic Microangiopathy Responsive to Therapeutic Plasma Exchange and Eculizumab Therapy.

Authors:  Robert C Sterner; William Nicholas Rose
Journal:  Hematol Rep       Date:  2022-04-05

Review 6.  The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies.

Authors:  Claire Comerford; Siobhan Glavey; John Quinn; Jamie M O'Sullivan
Journal:  J Thromb Haemost       Date:  2022-06-23       Impact factor: 16.036

Review 7.  Thrombotic microangiopathy associated with proteasome inhibitors.

Authors:  Ahad Lodhi; Abhishek Kumar; Muhammad U Saqlain; Manish Suneja
Journal:  Clin Kidney J       Date:  2015-07-16

8.  Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma.

Authors:  Jan Van Keer; Michel Delforge; Daan Dierickx; Kathelijne Peerlinck; Evelyne Lerut; Ben Sprangers
Journal:  Case Rep Hematol       Date:  2016-05-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.